5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib
R. Srinivasan, D. Su, L. Stamatakis, M. Siddiqui +8 more
201439 citations
Semantic Scholar

